EU Medicines Regulation Achievements: EMA’...

By HEOR Staff Writer

March 16, 2026

The European Medicines Agency (EMA) Management Board highlights at its March 2026 meeting a robust year, with the adoption of the 2025 annual report...
Catalyzing Cardiovascular Health Innovation through Urban Interventions and C...
EMA Approval Submission for Teclistamab Multiple Myeloma Monotherapy
Enhertu Early Breast Cancer: FDA Priority Review for Reducing Recurrence Risk
EMA’s Clinical Trials Guidance for Enhancing Flexibility During Public ...
Portugal Clinical Trials Regulation: A Comprehensive Framework for EU Complia...
Harmonizing Non-Clinical Evaluation of Microbiome Medicinal Products in the EU
CHMP February 2026 Approvals: New Breakthroughs in Medicines and Biosimilars
EMA’s mCombriax Vaccine Recommendation
KEYTRUDA Padcev MIBC Survival: New Era in Treatment Revealed by KEYNOTE-B15 T...
Novartis Drug Discovery Innovation: Advancing Global Health Through Strategic...
BIC LEN HIV Treatment: New Single-Tablet Regimen Shows Promising Results in A...
NICE Approves Ruxolitinib Cream for Treating Vitiligo with Facial Involvement